|
1
|
de Groot P and Munden RF: Lung cancer
epidemiology, risk factors, and prevention. Radiol Clin North Am.
50:863–876. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Krawczyk P, Nicoś M, Ramlau R, Powrózek T,
Wojas-Krawczyk K, Sura S, Jarosz B, Szumiło J, Warda E,
Mazurkiewicz T, et al: The incidence of EGFR-activating mutations
in bone metastases of lung adenocarcinoma. Pathol Oncol Res.
20:107–112. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jiang X, de Groh M, Liu S, Liang H and
Morrison H: Rising incidence of adenocarcinoma of the lung in
Canada. Lung Cancer. 78:16–22. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger K, Yatabe Y, Powell CA, Beer D, Riely G,
Garg K, et al: International Association for the Study of Lung
Cancer/American Thoracic Society/European Respiratory Society:
International multidisciplinary classification of lung
adenocarcinoma: Executive summary. Proc Am Thorac Soc. 8:381–385.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lei B, Qi W, Zhao Y, Li Y, Liu S, Xu X,
Zhi C, Wan L and Shen H: PBK/TOPK expression correlates with mutant
p53 and affects patients' prognosis and cell proliferation and
viability in lung adenocarcinoma. Hum Pathol. 46:217–224. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hu F, Gartenhaus RB, Eichberg D, Liu Z,
Fang HB and Rapoport AP: PBK/TOPK interacts with the DBD domain of
tumor suppressor p53 and modulates expression of transcriptional
targets including p21. Oncogene. 29:5464–5474. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Park JH, Lin ML, Nishidate T, Nakamura Y
and Katagiri T: PDZ-binding kinase/T-LAK cell-originated protein
kinase, a putative cancer/testis antigen with an oncogenic activity
in breast cancer. Cancer Res. 66:9186–9195. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gaudet S, Branton D and Lue RA:
Characterization of PDZ-binding kinase, a mitotic kinase. Proc Natl
Acad Sci USA. 97:5167–5172. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Simons-Evelyn M, Bailey-Dell K, Toretsky
JA, Ross DD, Fenton R, Kalvakolanu D and Rapoport AP: PBK/TOPK is a
novel mitotic kinase which is upregulated in Burkitt's lymphoma and
other highly proliferative malignant cells. Blood Cells Mol Dis.
27:825–829. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ayllón V and O'connor R: PBK/TOPK promotes
tumour cell proliferation through p38 MAPK activity and regulation
of the DNA damage response. Oncogene. 26:3451–3461. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stricker TP, Henriksen KJ, Tonsgard JH,
Montag AG, Krausz TN and Pytel P: Expression profiling of 519
kinase genes in matched malignant peripheral nerve sheath
tumor/plexiform neurofibroma samples is discriminatory and
identifies mitotic regulators BUB1B, PBK and NEK2 as overexpressed
with transformation. Mod Pathol. 26:930–943. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim DJ, Li Y, Reddy K, Lee MH, Kim MO, Cho
YY, Lee SY, Kim JE, Bode AM and Dong Z: Novel TOPK inhibitor
HI-TOPK-032 effectively suppresses colon cancer growth. Cancer Res.
72:3060–3068. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Herrero-Martín D, Osuna D, Ordóñez JL,
Sevillano V, Martins AS, Mackintosh C, Campos M, Madoz-Gúrpide J,
Otero-Motta AP, Caballero G, et al: Stable interference of EWS-FLI1
in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signaling and
reveals TOPK as a new target. Br J Cancer. 101:80–90. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lei B, Liu S, Qi W, Zhao Y, Li Y, Lin N,
Xu X, Zhi C, Mei J, Yan Z, et al: PBK/TOPK expression in
non-small-cell lung cancer: Its correlation and prognostic
significance with Ki67 and p53 expression. Histopathology.
63:696–703. 2013.PubMed/NCBI
|
|
16
|
Ohashi T, Komatsu S, Ichikawa D, Miyamae
M, Okajima W, Imamura T, Kiuchi J, Kosuga T, Konishi H, Shiozaki A,
et al: Overexpression of PBK/TOPK relates to tumour malignant
potential and poor outcome of gastric carcinoma. Br J Cancer.
116:218–226. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang CF, Chen SL, Sung WW, Hsieh MJ, Hsu
HT, Chen LH, Chen MK, Ko JL, Chen CJ and Chou MC: PBK/TOPK
expression predicts prognosis in oral cancer. Int J Mol Sci.
17:2016. View Article : Google Scholar
|
|
18
|
Hu F, Gartenhaus RB, Zhao XF, Fang HB,
Minkove S, Poss DE and Rapoport AP: c-Myc and E2F1 drive PBK/TOPK
expression in high-grade malignant lymphomas. Leuk Res. 37:447–454.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Inui M, Martello G and Piccolo S: MicroRNA
control of signal transduction. Nat Rev Mol Cell Biol. 11:252–263.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Png KJ, Halberg N, Yoshida M and Tavazoie
SF: A microRNA regulon that mediates endothelial recruitment and
metastasis by cancer cells. Nature. 481:190–194. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ameres SL and Zamore PD: Diversifying
microRNA sequence and function. Nat Rev Mol Cell Biol. 14:475–488.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
He S, Liao B, Deng Y, Su C, Tuo J, Liu J,
Yao S and Xu L: miR-216b inhibits cell proliferation by targeting
FOXM1 in cervical cancer cells and is associated with better
prognosis. BMC Cancer. 17:6732017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang T, Ma G, Zhang Y, Huo H and Zhao Y:
miR-216b inhibits glioma cell migration and invasion through
suppression of FoxM1. Oncol Rep. 38:1751–1759. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu Y, Niu Z, Lin X and Tian Y: miR-216b
increases cisplatin sensitivity in ovarian cancer cells by
targeting PARP1. Cancer Gene Ther. 24:208–214. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu FY, Zhou SJ, Deng YL, Zhang ZY, Zhang
EL, Wu ZB, Huang ZY and Chen XP: miR-216b is involved in
pathogenesis and progression of hepatocellular carcinoma through
HBx-miR-216b-IGF2BP2 signaling pathway. Cell Death Dis.
6:e16702015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Meng SF, Mao WP, Wang F, Liu XQ and Shao
LL: The relationship between Cd-induced autophagy and lysosomal
activation in WRL-68 cells. J Appl Toxicol. 35:1398–1405. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Feng YL, Yin YX, Ding J, Yuan H, Yang L,
Xu JJ and Hu LQ: Alpha-1-antitrypsin suppresses oxidative stress in
preeclampsia by inhibiting the p38MAPK signaling pathway: An in
vivo and in vitro study. PLoS One. 12:e01737112017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zou J, Kuang W, Hu J and Rao H: miR-216b
promotes cell growth and enhances chemosensitivity of colorectal
cancer by suppressing PDZ-binding kinase. Biochem Biophys Res
Commun. 488:247–252. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gao S, Li X, Ding X, Qi W and Yang Q:
Cepharanthine Induces autophagy, apoptosis and cell cycle arrest in
breast cancer cells. Cell Physiol Biochem. 41:1633–1648. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rottiers V, Najafi-Shoushtari SH, Kristo
F, Gurumurthy S, Zhong L, Li Y, Cohen DE, Gerszten RE, Bardeesy N,
Mostoslavsky R and Näär AM: MicroRNAs in metabolism and metabolic
diseases. Cold Spring Harb Symp Quant Biol. 76:225–233. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Singh PK, Srivastava AK, Dalela D, Rath
SK, Goel MM and Bhatt ML: Expression of PDZ-binding kinase/T-LAK
celloriginated protein kinase (PBK/TOPK) in human urinary bladder
transitional cell carcinoma. Immunobiology. 219:469–474. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Joel M, Mughal AA, Grieg Z, Murrell W,
Palmero S, Mikkelsen B, Fjerdingstad HB, Sandberg CJ, Behnan J,
Glover JC, et al: Targeting PBK/TOPK decreases growth and survival
of glioma initiating cells in vitro and attenuates tumor growth in
vivo. Mol Cancer. 14:1212015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Riley T, Sontag E, Chen P and Levine A:
Transcriptional control of human p53-regulated genes. Nat Rev Mol
Cell Biol. 9:402–412. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu X, Wilcken R, Joerger AC, Chuckowree
IS, Amin J, Spencer J and Fersht AR: Small molecule induced
reactivation of mutant p53 in cancer cells. Nucleic Acids Res.
41:6034–6044. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Muller PA and Vousden KH: p53 mutations in
cancer. Nat Cell Biol. 15:2–8. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jackson JG and Lozano G: The mutant p53
mouse as a pre-clinical model. Oncogene. 32:4325–4330. 2013.
View Article : Google Scholar : PubMed/NCBI
|
